Viewing Study NCT00569127


Ignite Creation Date: 2025-12-25 @ 5:19 AM
Ignite Modification Date: 2025-12-26 @ 4:26 AM
Study NCT ID: NCT00569127
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-12-05
First Post: 2007-12-05
Is NOT Gene Therapy: False
Has Adverse Events: True

Brief Title: Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Sponsor: National Cancer Institute (NCI)
Organization: